What Is The Prism Phenotype In Copd?

If you or someone you love has COPD, you may have come across the term “prism phenotype” and wondered what it means. The prism phenotype is a proposed subgroup of chronic obstructive pulmonary disease (COPD) defined by three co-existing conditions: preserved ratio impaired spirometry (PRISm), obesity, and type 2 diabetes. Researchers have suggested that people who fit this profile may have a distinct pattern of symptoms, disease progression, and treatment response compared with other COPD patients. It remains a research concept, not an established clinical diagnosis.

What Is The Prism Phenotype In COPD?

The term “prism phenotype” was introduced to describe a specific cluster of patients with COPD who share three features at the same time. The name is an acronym built from the initials of those features.

• P — PRISm, or preserved ratio impaired spirometry. This means a person’s FEV1/FVC ratio is at or above 0.70 (the threshold that would normally rule out airflow obstruction), but their FEV1 is still below 80% of the predicted value. In other words, lung function is reduced, but the usual ratio-based definition of obstruction is not met.
• R — This letter is sometimes used to represent “ratio” as part of the PRISm acronym itself, or in some descriptions stands for “reduced” lung function. The exact expansion varies in the literature.
• I — Impaired fasting glucose or type 2 diabetes. This reflects a metabolic disturbance that often accompanies obesity.
• S — Sarcopenic obesity, meaning excess body fat combined with low muscle mass.
• M — Metabolic syndrome, a cluster of conditions including high blood pressure, elevated blood sugar, excess abdominal fat, and abnormal cholesterol levels.

Some descriptions of the prism phenotype emphasize PRISm, obesity, and diabetes as the three core components. Others include the broader metabolic syndrome and sarcopenic obesity. The inconsistency in how the phenotype is defined is one reason it has not been formally adopted into clinical guidelines.

What makes this concept interesting is that it cuts across the traditional way COPD is classified. Most COPD diagnosis and treatment is based on spirometry — specifically the ratio of FEV1 to FVC. But a growing body of research suggests that some patients with respiratory symptoms and reduced lung function do not fit neatly into the obstruction category. They may have a different underlying biology, different symptoms, and potentially different responses to treatment.

How Is PRISm Different From Classic COPD?

Classic COPD is defined by airflow obstruction that does not fully reverse. The key spirometric criterion is a post-bronchodilator FEV1/FVC ratio below 0.70. That ratio is the foundation of the diagnosis.

PRISm breaks that rule. In PRISm, the FEV1/FVC ratio stays at or above 0.70, but the FEV1 is reduced below 80% of predicted. The lungs are not moving air as well as they should, but the ratio-based definition of obstruction is not met. This means a person can have meaningful breathing problems and still not be diagnosed with COPD under the standard criteria.

Research has shown that people with PRISm often have symptoms similar to COPD — shortness of breath, cough, reduced exercise tolerance — and they may experience exacerbations. Some studies suggest that a portion of people with PRISm go on to develop classic COPD over time, while others remain stable or improve. The evidence here is still developing.

The overlap between PRISm and COPD matters because treatment decisions are often driven by the COPD diagnosis. If a patient has PRISm but not obstruction, they may not receive the same medications or pulmonary rehabilitation referrals. Whether that is the right approach is an open question.

Why Does Obesity Matter In This COPD Subgroup?

Obesity is common in people with COPD, and it complicates the picture in several ways. Excess body weight increases the work of breathing. It pushes against the diaphragm, reduces lung volumes, and can worsen breathlessness. At the same time, obesity is associated with type 2 diabetes and metabolic syndrome, which are systemic inflammatory conditions.

The prism phenotype links these metabolic factors to lung function. The idea is that chronic low-grade inflammation from excess fat tissue — particularly visceral fat — may contribute to airway disease or make it worse. This is not just a mechanical effect of weight on the chest wall. It is a biological interaction between metabolic dysfunction and lung health.

Sarcopenic obesity adds another layer. When a person has too much fat and too little muscle, their physical function suffers. They may struggle with exercise, have reduced strength, and be more prone to falls or disability. In COPD, low muscle mass is already associated with worse outcomes. Combining that with obesity creates a particularly challenging clinical picture.

Some clinicians have suggested that weight loss and metabolic control could improve outcomes in this group. But no large randomized trials have confirmed that targeting obesity or diabetes specifically changes the course of COPD in prism phenotype patients. The evidence is limited.

What Are The Symptoms And Risks?

People who fit the prism phenotype may experience a range of symptoms. These can include:

• Shortness of breath with exertion
• Chronic cough or sputum production
• Reduced exercise capacity
• Fatigue
• Frequent respiratory infections or exacerbations
• Symptoms related to diabetes or metabolic syndrome, such as increased thirst, frequent urination, or numbness in the feet

The risks associated with this phenotype are not fully understood. Some research suggests that people with PRISm have a higher risk of developing COPD, cardiovascular disease, and other chronic conditions compared with people with normal lung function. Obesity and diabetes independently increase the risk of heart disease, stroke, and other complications.

What is not clear is whether the combination of PRISm, obesity, and diabetes creates a risk that is greater than the sum of its parts. Some studies suggest that the metabolic and respiratory problems interact in ways that accelerate decline. Other studies have not found a clear synergistic effect. The evidence is mixed.

How Is The Prism Phenotype Identified?

There is no standard test for the prism phenotype. Identification relies on finding the individual components through routine clinical assessment.

PRISm is identified through spirometry. A post-bronchodilator FEV1/FVC ratio of 0.70 or higher with an FEV1 below 80% of predicted meets the criteria. This is a pattern that some clinicians may overlook if they are focused only on the ratio.

Obesity is typically assessed using body mass index (BMI). A BMI of 30 or higher is classified as obesity. Waist circumference and body composition measurements can provide additional information, especially for identifying sarcopenic obesity.

Type 2 diabetes is diagnosed through fasting glucose, oral glucose tolerance testing, or HbA1c measurement. Fasting glucose of 126 mg/dL or higher, or an HbA1c of 6.5% or higher, meets the diagnostic threshold for diabetes. Prediabetes is defined as fasting glucose between 100 and 125 mg/dL or HbA1c between 5.7% and 6.4%.

Metabolic syndrome is diagnosed when a person has at least three of five specific criteria: elevated waist circumference, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, or elevated fasting glucose. These thresholds are well established in clinical guidelines.

Because the prism phenotype is a research construct, no formal diagnostic code exists for it. A clinician might note that a patient has PRISm, obesity, and diabetes, but would not typically label them as having “prism phenotype COPD” in the medical record.

Does The Prism Phenotype Change Treatment?

Not yet. No clinical guidelines recommend treating prism phenotype patients differently from other COPD patients. The concept is still being studied to see whether it predicts response to specific therapies.

That said, the individual components of the phenotype each have established treatments. Obesity management may include lifestyle changes, behavioral therapy, medications, or bariatric surgery in selected cases. Type 2 diabetes is treated with diet, exercise, oral medications, or insulin. PRISm itself has no specific approved therapy, but clinicians may treat symptoms with bronchodilators or inhaled corticosteroids based on the patient’s overall presentation.

Pulmonary rehabilitation is often recommended for people with COPD and may benefit those with PRISm as well, especially if they have reduced exercise capacity. However, no studies have specifically tested pulmonary rehabilitation in prism phenotype patients.

Some researchers have raised the possibility that anti-inflammatory treatments targeting metabolic pathways could help. But this is speculative. No trial has demonstrated that treating the metabolic component improves lung function or symptoms in this group.

The most honest position is that the prism phenotype is a useful way to think about a subgroup of patients who may have been overlooked or undertreated because they do not fit the classic COPD definition. It is not a guide to treatment — at least not yet.

What Does The Research Say?

Research on PRISm and the prism phenotype is growing but still limited. Studies have shown that people with PRISm are more likely to have respiratory symptoms, reduced quality of life, and increased healthcare use compared with people with normal spirometry. Some studies have found that PRISm is associated with a higher risk of progression to COPD.

The addition of obesity and diabetes to the picture comes from research into COPD phenotypes more broadly. Scientists have been trying to identify subgroups of COPD patients who share clinical features, biomarkers, or genetic profiles. The goal is to move toward precision medicine — matching treatments to the underlying biology of each patient.

The prism phenotype is one attempt at that. But it has not been validated in large, diverse populations. Most studies have been retrospective or based on specific cohorts. The definitions vary. And no study has shown that identifying someone as having the prism phenotype leads to better outcomes.

That does not mean the concept is useless. It may help clinicians remember to look for metabolic problems in COPD patients and to consider PRISm when spirometry does not show obstruction. It may also stimulate research into whether treating obesity or diabetes can improve lung health. But it is not a diagnosis, and it is not a treatment plan.